Pfizer’s COVID Vaccine on Hold for Infants/Toddlers
The FDA has just announced that they plan to postpone their scheduled advisory committee meeting on Pfizer’s COVID-19 vaccine for children ages 6 months to 4 years. They do not expect to reconvene for a few more months pending additional data required to move forward.
A two-dose vaccine series failed to meet “immunobridging” criteria in a study evaluating the youngest children. Pfizer explained in a previous statement that a third dose “may provide a higher level of protection in this age group.” The ongoing clinical study plans to evaluate a third dose at least two months after the second dose of the two-dose series in this age group of children.
The FDA ultimately decided that “additional time regarding a third dose should be considered,” and postponed the advisory committee meeting until further data was available.
Read full MedPage Today Article here
Read Pfizer’s statement here
Read additional LDA articles on COVID vaccines here